Drug Substance Facilities – Hidden and Critical Intermediate
Major Issues and Facilities in Drug Master Files (9/15) Global Quality
Drug Substance Quality Assessment: Best Practices (23of27) Generic Drugs Forum 2018
FDA Inspections of Compounding Outsourcing Facilities
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
Drug Substance, Drug Products and Excipients
Modernizing Drug Substance Assessment through KASA
503B Product Reporting for Compounding Outsourcing Facilities (7/7) Drug Registration & Listing 2018
How Biologic Medicines Are Made | How It's Made
Common CMC Issues in Type II DMFs and How to Avoid Them
Virtually Visit Our Biologics Drug Substance Facility in Madison, Wisconsin
BioPhorum Drug Substance introduces workstreams: Cell Banks, LIVCA and Multi Product Facility (1/4)
API Facility Inspections
Lifecycle Changes to Chemistry, Manufacture, and Controls in NDAs - REdI 2020
Questions and Answers on Drug Master Files (DMFs) and Drug Substances Part I
I-Team: Drug rehab center bills patient's insurance nearly $1,000 a day for drug testing
OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2023 User Fees and Registration
Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum
Psychology Professor & Substance Abuse Counselor | Andrew Assini | TEDxPittsburghStatePrison
What are APIs (Active Pharmaceutical Ingredients)?
